Unconventional mechanism of action and resistance to rapalogs in renal cancer
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2310793121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Juan Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Mechanistic Target of Rapamycin Complex 1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute (NCI).
Abstract (Originalsprache)
mTORC1 is aberrantly activated in renal cell carcinoma (RCC) and is targeted by rapalogs. As for other targeted therapies, rapalogs clinical utility is limited by the development of resistance. Resistance often results from target mutation, but mTOR mutations are rarely found in RCC. As in humans, prolonged rapalog treatment of RCC tumorgrafts (TGs) led to resistance. Unexpectedly, explants from resistant tumors became sensitive both in culture and in subsequent transplants in mice. Notably, resistance developed despite persistent mTORC1 inhibition in tumor cells. In contrast, mTORC1 became reactivated in the tumor microenvironment (TME). To test the role of the TME, we engineered immunocompromised recipient mice with a resistance mTOR mutation (S2035T). Interestingly, TGs became resistant to rapalogs in mTOR S2035T mice. Resistance occurred despite mTORC1 inhibition in tumor cells and could be induced by coculturing tumor cells with mutant fibroblasts. Thus, enforced mTORC1 activation in the TME is sufficient to confer resistance to rapalogs. These studies highlight the importance of mTORC1 inhibition in nontumor cells for rapalog antitumor activity and provide an explanation for the lack of mTOR resistance mutations in RCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852.
- Hematology-Oncology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852.
- Department of Pediatrics, Dell Medical School, University of Texas at Austin, Austin, TX 78723.
- Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390-8816.
- Quantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX 75390-8821.
- Oncology R&D Group, Pfizer Worldwide Research and Development, San Diego, CA 92121.
ORCID-Profile: Ramesh Butti, Shannon Cohn, Vanina Toffessi-Tcheuyap, Arijit Mal, Alana Christie, Jiwoong Kim, Payal Kapur, James Brugarolas
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Yang, J., Butti, R., Cohn, S., Toffessi-Tcheuyap, V., Mal, A., Nguyen, M., Stevens, C., Christie, A., Mishra, A., Ma, Y., Kim, J., Abraham, R., Kapur, P., Hammer, R. E., & Brugarolas, J. (2024). Unconventional mechanism of action and resistance to rapalogs in renal cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2310793121
Vancouver
Yang J, Butti R, Cohn S, Toffessi-Tcheuyap V, Mal A, Nguyen M, et al. Unconventional mechanism of action and resistance to rapalogs in renal cancer. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2310793121
BibTeX
@article{Yang2024,
author = {Yang, Juan and Butti, Ramesh and Cohn, Shannon and Toffessi-Tcheuyap, Vanina and Mal, Arijit and Nguyen, Mylinh and Stevens, Christina and Christie, Alana and Mishra, Akhilesh and Ma, Yuanqing and Kim, Jiwoong and Abraham, Robert and Kapur, Payal and Hammer, Robert E and Brugarolas, James},
title = {Unconventional mechanism of action and resistance to rapalogs in renal cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2310793121}
}
EUVIMED